Evidence map›Paper›PMID 34997441›Full record

ArticleMolecular diversity2022

Anthranilamides with quinoline and β-carboline scaffolds: design, synthesis, and biological activity.

Maja Beus, Leentje Persoons, Dirk Daelemans, Dominique Schols, Kirsi Savijoki, Pekka Varmanen, Jari Yli-Kauhaluoma, Kristina Pavić, Branka Zorc

Open access · bronzeAbstract read
In one paragraph

Article in Molecular diversity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Maja BeusDepartment of Medicinal Chemistry, Faculty of Pharmacy and Biochemistry, University of Zagreb, 10 000, Zagreb, Croatia.
Leentje PersoonsLaboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, KU Leuven, Rega Institute, 3000, Leuven, Belgium.
Dirk DaelemansLaboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, KU Leuven, Rega Institute, 3000, Leuven, Belgium.
Dominique ScholsLaboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, KU Leuven, Rega Institute, 3000, Leuven, Belgium.
Kirsi SavijokiDrug Research Program, Division of Pharmaceutical Biosciences, University of Helsinki, 00014, Helsinki, Finland.
Pekka VarmanenDepartment of Food and Nutrition, University of Helsinki, 00014, Helsinki, Finland.
Jari Yli-KauhaluomaDrug Research Program, Division of Pharmaceutical Chemistry and Technology, University of Helsinki, 00014, Helsinki, Finland.
Kristina PavićDepartment of Medicinal Chemistry, Faculty of Pharmacy and Biochemistry, University of Zagreb, 10 000, Zagreb, Croatia.
Branka ZorcDepartment of Medicinal Chemistry, Faculty of Pharmacy and Biochemistry, University of Zagreb, 10 000, Zagreb, Croatia. bzorc@pharma.hr.ORCID http://orcid.org/0000-0003-4355-8816
Rega Institute for Medical Research · BEUniversity of Helsinki · FIUniversity of Zagreb · HR

Funding

Hrvatska Zaklada za Znanost IP-09-2014-1501Itä-Suomen Yliopisto 322012Itä-Suomen Yliopisto 325784
6 · The paper itself

Abstract

In the present study, we report the design and synthesis of novel amide-type hybrid molecules based on anthranilic acid and quinoline or β-carboline heterocyclic scaffolds. Three types of biological screenings were performed: (i) in vitro antiproliferative screening against a panel of solid tumor and leukemia cell lines, (ii) antiviral screening against several RNA viruses, and (iii) anti-quorum sensing screening using gram-negative Chromobacterium violaceum as the reporter strain. Antiproliferative screening revealed a high activity of several compounds. Anthranilamides 12 and 13 with chloroquine core and halogenated anthranilic acid were the most active agents toward diverse cancer cell lines such as glioblastoma, pancreatic adenocarcinoma, colorectal carcinoma, lung carcinoma, acute lymphoblastic, acute myeloid, chronic myeloid leukemia, and non-Hodgkin lymphoma, but also against noncancerous cell lines. Boc-protected analogs 2 and 3 showed moderate activities against the tested cancer cells without toxic effects against noncancerous cells. A nonhalogenated quinoline derivative 10 with N-benzylanthranilic acid residue was equally active as 12 and 13 and selective toward tumor cells. Chloroquine and quinoline anthranilamides 10-13 exerted pronounced antiviral effect against human coronaviruses 229E and OC43, whereas 12 and 13 against coronavirus OC43 (EC

Indexed as

AdenocarcinomaPancreatic NeoplasmsQuinolinesAmidesAnti-Bacterial AgentsAntiviral AgentsCarbolinesChloroquineHumansortho-AminobenzoatesAmidesanthranilamideanthranilic acidAnti-Bacterial AgentsAntiviral AgentsCarbolinesChloroquineortho-AminobenzoatesQuinolinesAnthranilamideAnticancerAntiviralQuinolineQuorum sensing (QS) inhibitionβ-Carboline

Identifiers

PMID34997441
PMCPMC8741576
OpenAlexW4206385916

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.